title: [Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate].
abstract: The lanthanum carbonate which is the new phosphate binder decreased serum phosphorus value significantly in comparison with the placebo group, showed equal serum phosphorus decrease action to those at the capacity which in addition is less than calcium carbonate and sevelamer hydrochloride.
authors.affiliation: Wakayama Medical University, Division of Nephrology and Blood Purification Medicine.
authors.forename: Koichi
authors.initials: K
authors.lastname: Tatsuta
authors.forename: Takashi
authors.initials: T
authors.lastname: Shigematsu
mesh_terms: D002908:Chronic Disease; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology*; D007674:Kidney Diseases / Q000150:complications*; D007811:Lanthanum / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: C119467:lanthanum carbonate; D007811:Lanthanum